Related content

Hypoxia as a target for combined modality treatments

By Wouters B.G.   Weppler S.A.   Koritzinsky M.   Landuyt W.   Nuyts S.   Theys J.   Chiu R.K.   Lambin P.  

European Journal of Cancer, Vol. 38, Iss. 2, 2002-01 ,pp. : 240-257

Elsevier

Access to resources Recommend Favorite

DNA-Topoisomerase I, a new target for the treatment of neuroblastoma

By Vassal G.   Pondarre C.   Cappelli C.   Terrier-Lacombe M.J.   Boland I.   Morizet J.   Benard J.   Venuat A.M.   Ardouin P.   Hartmann O.   Gouyette A.  

European Journal of Cancer, Vol. 33, Iss. 12, 1997-10 ,pp. : 2011-2015

Elsevier

Access to resources Recommend Favorite

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

By                          

Experimental and Therapeutic Medicine, Vol. 3, Iss. 2, 2012-01 ,pp. : 207-213

Spandidos Publications

Access to resources Recommend Favorite

The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells

By Bence Aimee   Mattingly Cynthia   Burke Thomas   Adams Val  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 354-360

Springer Publishing Company

Access to resources Recommend Favorite

Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines

By        

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1053-1058

Spandidos Publications

Access to resources Recommend Favorite